These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27766741)

  • 21. Oral vaccination with Lactococcus lactis expressing the Vibrio cholerae Wzm protein to enhance mucosal and systemic immunity.
    Zamri HF; Shamsudin MN; Rahim RA; Neela V
    Vaccine; 2012 May; 30(21):3231-8. PubMed ID: 22426330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes.
    Ebrahimizadeh W; Mousavi Gargari S; Rajabibazl M; Safaee Ardekani L; Zare H; Bakherad H
    Appl Microbiol Biotechnol; 2013 May; 97(10):4457-66. PubMed ID: 23135228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral immunization with a probiotic cholera vaccine induces broad protective immunity against Vibrio cholerae colonization and disease in mice.
    Sit B; Zhang T; Fakoya B; Akter A; Biswas R; Ryan ET; Waldor MK
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007417. PubMed ID: 31150386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.
    Johnson RA; Uddin T; Aktar A; Mohasin M; Alam MM; Chowdhury F; Harris JB; LaRocque RC; Bufano MK; Yu Y; Wu-Freeman Y; Leung DT; Sarracino D; Krastins B; Charles RC; Xu P; Kovác P; Calderwood SB; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2012 Nov; 19(11):1712-21. PubMed ID: 22993410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variable gene family usage of protective and non-protective anti-Vibrio cholerae O1 LPS antibody heavy chains.
    Wade TK; Wade WF
    Microbiol Immunol; 2008 Dec; 52(12):611-20. PubMed ID: 19120975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodies.
    Attridge SR; Holmgren J
    Microb Pathog; 2009 Dec; 47(6):314-20. PubMed ID: 19818394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh.
    Aktar A; Rahman MA; Afrin S; Faruk MO; Uddin T; Akter A; Sami MIN; Yasmin T; Chowdhury F; Khan AI; Leung DT; LaRocque RC; Charles RC; Bhuiyan TR; Mandlik A; Kelly M; Kováč P; Xu P; Calderwood SB; Harris JB; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2016 May; 23(5):427-435. PubMed ID: 27009211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A polyvalent multiepitope protein cross-protects against
    Upadhyay I; Li S; Ptacek G; Seo H; Sack DA; Zhang W
    Proc Natl Acad Sci U S A; 2022 Dec; 119(50):e2202938119. PubMed ID: 36469767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide.
    Alam MM; Bufano MK; Xu P; Kalsy A; Yu Y; Freeman YW; Sultana T; Rashu MR; Desai I; Eckhoff G; Leung DT; Charles RC; LaRocque RC; Harris JB; Clements JD; Calderwood SB; Qadri F; Vann WF; Kováč P; Ryan ET
    PLoS Negl Trop Dis; 2014 Feb; 8(2):e2683. PubMed ID: 24516685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh.
    Aktar A; Rahman MA; Afrin S; Akter A; Uddin T; Yasmin T; Sami MIN; Dash P; Jahan SR; Chowdhury F; Khan AI; LaRocque RC; Charles RC; Bhuiyan TR; Mandlik A; Kelly M; Kováč P; Xu P; Calderwood SB; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006399. PubMed ID: 29684006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral vaccine against cholera prepared from Vibrio cholerae antigen(s).
    Chaicumpa W; Chaisri U; Tapchaisri P; Chongsa-Nguan M; Pongponratn E
    Southeast Asian J Trop Med Public Health; 1987 Jun; 18(2):142-8. PubMed ID: 3313733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.
    Grandjean C; Boutonnier A; Dassy B; Fournier JM; Mulard LA
    Glycoconj J; 2009 Jan; 26(1):41-55. PubMed ID: 18648931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A.
    Wade TK; Saksena R; Shiloach J; Kovác P; Wade WF
    FEMS Immunol Med Microbiol; 2006 Nov; 48(2):237-51. PubMed ID: 17010106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies.
    Grandjean C; Wade TK; Ropartz D; Ernst L; Wade WF
    Pathog Dis; 2013 Mar; 67(2):136-58. PubMed ID: 23620159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae.
    Attridge SR; Rowley D
    J Infect Dis; 1983 Nov; 148(5):931-9. PubMed ID: 6195273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of stable Vibrio cholerae O1 Hikojima type vaccine strains co-expressing the Inaba and Ogawa lipopolysaccharide antigens.
    Karlsson SL; Ax E; Nygren E; Källgård S; Blomquist M; Ekman A; Benktander J; Holmgren J; Lebens M
    PLoS One; 2014; 9(11):e108521. PubMed ID: 25397871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.